Skip to main content
Journal cover image

Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.

Publication ,  Journal Article
Chawana, TD; Walsh, SR; Stranix-Chibanda, L; Chirenje, ZM; Yu, C; Zhang, L; Seaton, KE; Heptinstall, J; Zhang, L; Paez, CA; Gamble, T; Gay, CL ...
Published in: BMC Immunol
February 19, 2025

VRC07-523LS is a safe and well-tolerated monoclonal antibody (mAb) targeting the CD4 binding site on the HIV envelope (Env) trimer. Efficacy of VRC07-523LS, in combination with mAbs targeting other HIV epitopes, will be evaluated in upcoming trials to prevent HIV acquisition in adults. However, differences in the pharmacokinetics (PK) of VRC07-523LS when administered alone vs. in combination with other mAbs have not been formally assessed. We performed a cross-protocol analysis of three clinical trials and included data from a total of 146 adults without HIV who received intravenous (n = 95) or subcutaneous (n = 51) VRC07-523LS, either alone ('single'; n = 100) or in combination with 1 or 2 other mAbs ('combined'; n = 46). We used an open, two-compartment population PK model to describe serum concentrations of VRC07-523LS over time, accounting for inter-individual variabilities. We compared individual-level PK parameters between the combined vs. single groups using the targeted maximum likelihood estimation method to adjust for participant characteristics. No significant differences were observed in clearance rate, inter-compartmental clearance, distribution half-life, or total VRC07-523LS exposure over time. However, for the combined group, mean central volume of distribution, peripheral volume of distribution, and elimination half-life were slightly greater, corresponding to slightly lower predicted concentrations early post-administration with high levels being maintained in both groups. These results suggest potential PK interactions between VRC07-523LS and other mAbs, but with small clinical impact in the context of HIV prevention. Our findings support coadministration of VRC07-523LS with other mAbs, and the use of the developed PK models to design future trials for HIV prevention.

Duke Scholars

Published In

BMC Immunol

DOI

EISSN

1471-2172

Publication Date

February 19, 2025

Volume

26

Issue

1

Start / End Page

8

Location

England

Related Subject Headings

  • Young Adult
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Female
  • Broadly Neutralizing Antibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chawana, T. D., Walsh, S. R., Stranix-Chibanda, L., Chirenje, Z. M., Yu, C., Zhang, L., … HVTN 127/HPTN 087, HVTN 130/HPTN 089 and HVTN 136/HPTN 092 Study Teams. (2025). Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV. BMC Immunol, 26(1), 8. https://doi.org/10.1186/s12865-025-00687-7
Chawana, Tariro D., Stephen R. Walsh, Lynda Stranix-Chibanda, Zvavahera M. Chirenje, Chenchen Yu, Lily Zhang, Kelly E. Seaton, et al. “Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.BMC Immunol 26, no. 1 (February 19, 2025): 8. https://doi.org/10.1186/s12865-025-00687-7.
Chawana, Tariro D., et al. “Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.BMC Immunol, vol. 26, no. 1, Feb. 2025, p. 8. Pubmed, doi:10.1186/s12865-025-00687-7.
Chawana TD, Walsh SR, Stranix-Chibanda L, Chirenje ZM, Yu C, Zhang L, Seaton KE, Heptinstall J, Paez CA, Gamble T, Karuna ST, Andrew P, Hanscom B, Sobieszczyk ME, Edupuganti S, Gay CL, Mannheimer SB, Hurt CB, Stephenson KE, Polakowski LL, Spiegel H, Yacovone M, Regenold S, Yen C, Baumblatt JA, Gama L, Barouch DH, Piwowar-Manning E, Koup RA, Tomaras GD, Hyrien O, Roxby AC, Huang Y, HVTN 127/HPTN 087, HVTN 130/HPTN 089 and HVTN 136/HPTN 092 Study Teams. Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV. BMC Immunol. 2025 Feb 19;26(1):8.
Journal cover image

Published In

BMC Immunol

DOI

EISSN

1471-2172

Publication Date

February 19, 2025

Volume

26

Issue

1

Start / End Page

8

Location

England

Related Subject Headings

  • Young Adult
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Female
  • Broadly Neutralizing Antibodies